Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A

Wouter B Nagengast, Elmire Hartmans, Pilar B Garcia-Allende, Frans T M Peters, Matthijs D Linssen, Maximilian Koch, Marjory Koller, Jolien J J Tjalma, Arend Karrenbeld, Annelies Jorritsma-Smit, Jan H Kleibeuker, Gooitzen M van Dam, Vasilis Ntziachristos, Wouter B Nagengast, Elmire Hartmans, Pilar B Garcia-Allende, Frans T M Peters, Matthijs D Linssen, Maximilian Koch, Marjory Koller, Jolien J J Tjalma, Arend Karrenbeld, Annelies Jorritsma-Smit, Jan H Kleibeuker, Gooitzen M van Dam, Vasilis Ntziachristos

No abstract available

Keywords: angiogenesis; barrett; early detection; imaging; oesophageal cancer; tumor.

Conflict of interest statement

Competing interests: WBN and GMvD received an unrestricted research grant for molecular imaging development from SurgVision BV (the Netherlands). GMvD and VN are in the scientific advisory board of Surgvision BV. The other authors have no conflicts to declare.

Figures

Figure 1
Figure 1
Real-time VEGFA-targeted NIR-FME. (A) Schematic overview and timeline of the two NIR-FME approaches (n=14). (B) Examples of the systemic tracer based, and (C) the topical tracer results, summarising that all lesions could be visualised with NIR-FME, including one EAC area which was not visible during HD inspection (displayed in C—first row). (D) Additionally identified dysplastic areas during NIR-FME, which were missed during HD-NBI inspection. All fluorescence signals presented here are uncorrected; overlay images display the high intensities only. EAC, oesophageal adenocarcinoma; HD, high-definition; HGD, high-grade dysplasia; LGD, low-grade dysplasia; NIR-FME, near-infrared fluorescence molecular endoscopy; NBI, narrow-band imaging; VEGFA, antibody against vascular endothelial growth factor.
Figure 2
Figure 2
Ex vivo VEGFA and fluorescent signal analyses of study subjects. (A) Boxplot presenting IHC results (H-score: median, 10–90 percentile); a significant difference in VEGFA staining intensities is observed between the dysplastic and benign tissue sites (**P

References

    1. Jankowski M, Wani S. Diagnostic and management implications of basic science advances in barrett’s esophagus. Curr Treat Options Gastroenterol 2015;13:16–29. 10.1007/s11938-014-0040-9
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403. 10.1016/j.ejca.2012.12.027
    1. Pera M, Manterola C, Vidal O, et al. . Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005;92:151–9. 10.1002/jso.20357
    1. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Research. 182 Berlin, Heidelberg: Springer Berlin Heidelberg, 2010:1–17.
    1. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, et al. . Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med 2012;18:315–21. 10.1038/nm.2616
    1. Joshi BP, Wang TD. Gastrointestinal imaging in 2015: Emerging trends in endoscopic imaging. Nat Rev Gastroenterol Hepatol 2016;13:72–3. 10.1038/nrgastro.2015.214
    1. Atreya R, Goetz M. Molecular imaging in gastroenterology. Nat Rev Gastroenterol Hepatol 2013;10:704–12. 10.1038/nrgastro.2013.125
    1. Goetz M, Wang TD. Molecular imaging in gastrointestinal endoscopy. Gastroenterology 2010;138:828–33. 10.1053/j.gastro.2010.01.009
    1. Hoetker MS, Goetz M. Molecular imaging in endoscopy. United European Gastroenterol J 2013;1:84–92. SAGE Publications 10.1177/2050640613483291
    1. Bézière N, Ntziachristos V. Optoacoustic imaging: an emerging modality for the gastrointestinal tract. Gastroenterology 2011;141:1979–85. 10.1053/j.gastro.2011.10.006
    1. Sturm MB, Joshi BP, Lu S, et al. . Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 2013;5:184ra61–1. 10.1126/scitranslmed.3004733
    1. Joshi BP, Duan X, Kwon RS, et al. . Multimodal endoscope can quantify wide-field fluorescence detection of Barrett’s neoplasia. Endoscopy 2016;48 10.1055/s-0034-1392803
    1. Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol 2010;14:71–9. 10.1016/j.cbpa.2009.09.029
    1. Stollman TH, Scheer MG, Leenders WP, et al. . Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008;122:2310–4. 10.1002/ijc.23404
    1. Gaykema SB, Brouwers AH, Lub-de Hooge MN, et al. . 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013;54:1014–8. 10.2967/jnumed.112.117218
    1. Nagengast WB, de Korte MA, Oude Munnink TH, et al. . 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761–7. 10.2967/jnumed.109.071043
    1. Nagengast WB, de Vries EG, Hospers GA, et al. . In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313–9. 10.2967/jnumed.107.041301
    1. Griffiths EA, Pritchard SA, McGrath SM, et al. . Increasing expression of hypoxia-inducible proteins in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Br J Cancer 2007;96:1377–83. 10.1038/sj.bjc.6603744
    1. Möbius C, Stein HJ, Becker I, et al. . The ‘angiogenic switch’ in the progression from Barrett’s metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003;29:890–4. 10.1016/j.ejso.2003.07.002
    1. Folkman J, Watson K, Ingber D, et al. . Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61. 10.1038/339058a0
    1. Auvinen MI, Sihvo EI, Ruohtula T, et al. . Incipient angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s adenocarcinoma. J Clin Oncol 2002;20:2971–9. 10.1200/JCO.2002.09.011
    1. Kleespies A, Guba M, Jauch K-W, et al. . Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95–104. 10.1002/jso.20070

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다